Capirci Carlo, Valentini Vincenzo, Cionini Luca, De Paoli Antonino, Rodel Claus, Glynne-Jones Robert, Coco Claudio, Romano Mario, Mantello Giovanna, Palazzi Silvia, Mattia Falchetti Osti, Friso Maria Luisa, Genovesi Domenico, Vidali Cristiana, Gambacorta Maria Antonietta, Buffoli Alberto, Lupattelli Marco, Favretto Maria Silvia, La Torre Giuseppe
Department of Radiotherapy, State Hospital, Rovigo, Italy.
Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):99-107. doi: 10.1016/j.ijrobp.2007.12.019. Epub 2008 Apr 11.
In the literature, a favorable prognosis was observed for complete pathologic response after preoperative therapy (ypCR) in patients with locally advanced rectal cancer. The aim of this study is to verify whether ypCR predicts a favorable outcome in a large series of patients.
The Gastro-Intestinal Working Group of the Italian Association of Radiation Oncology collected clinical data for 566 patients with ypCR (ypT0N0) after neoadjuvant therapy. Eligibility criteria included locally advanced rectal cancer with no evidence of metastases at the time of diagnosis, evidence of ypCR after preoperative radiotherapy +/- chemotherapy (CT).
Median radiation dose was 50 Gy. A total of 527 patients (93%) received one of 12 different neoadjuvant CT schedules. Sphincter preservation, anteroposterior resection, and endoscopic surgery were performed in 73%, 22%, and 5% of patients, respectively. Adjuvant CT was administered to 22% of patients. Median follow-up was 46.4 months. Locoregional recurrence occurred in 7 patients (1.6%). Distant metastases occurred in 49 patients (8.9%). Overall, 5-year rates of disease-free survival, overall survival, and cancer-specific survival were 85%, 90%, and 94%, respectively. In multivariate analysis, only age and clinical stage statistically correlated with survival outcome. Adjuvant CT was still of borderline significance (worse for adjuvant CT). No relation was found between survival and neoadjuvant CT schedules.
A ypCR after neoadjuvant therapy identified a favorable group of patients, even in this large series of 566 patients collected in 61 centers. Locoregional recurrence occurred only in 1.6% patients.
在文献中,局部晚期直肠癌患者术前治疗后达到完全病理缓解(ypCR)的预后良好。本研究旨在验证ypCR是否能预测大量患者的良好预后。
意大利放射肿瘤学协会胃肠工作组收集了566例新辅助治疗后达到ypCR(ypT0N0)患者的临床数据。纳入标准包括诊断时为局部晚期直肠癌且无转移证据,术前放疗+/-化疗(CT)后有ypCR证据。
中位放疗剂量为50 Gy。共有527例患者(93%)接受了12种不同新辅助CT方案中的一种。分别有73%、22%和5%的患者接受了保肛手术、前后位切除术和内镜手术。22%的患者接受了辅助CT治疗。中位随访时间为46.4个月。7例患者(1.6%)发生了局部区域复发。49例患者(8.9%)发生了远处转移。总体而言,5年无病生存率、总生存率和癌症特异性生存率分别为85%、90%和94%。多因素分析中,仅年龄和临床分期与生存结果有统计学相关性。辅助CT仍具有临界显著性(辅助CT患者预后较差)。未发现生存与新辅助CT方案之间的关系。
新辅助治疗后达到ypCR的患者预后良好,即使在这个由61个中心收集的566例患者的大样本中也是如此。仅1.6%的患者发生了局部区域复发。